Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
2 hedge funds and large institutions have $67K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
10% more capital invested
Capital invested by funds: $61K → $67K (+$6K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.08K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $42K | +$2.08K | +1,000 | +5% |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $25K | – | – | – |
|
APOPW Hedge Fund Activity: Q2 2018 in Review
2 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q2 2018, worth a combined $67K — up 9.8% from $61K a quarter earlier.
Fund positioning in APOPW was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.08K.
- 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $67K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q2 2018, up 9.8% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q2 2018 and 0 closed out.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q2 2018 was Susquehanna International Group, an estimated $2.08K added.
Based on aggregated 13F filings for Q2 2018.